NAD+ Boosters Have A Celebrity Tier. The Human Data Is Still Smaller Than The Hype.

Pills run $30 to $80. Injections cost several hundred dollars. IV infusions can hit $1,000 per session. The NAD+ longevity industry has scaled fast on the promise that lifting NAD+ levels can rewind aspects of biological aging. NPR’s May 11, 2026 analysis lays out the gap between that marketing language and the underlying human data.

What NAD+ Is And Why It Falls

NAD+ (nicotinamide adenine dinucleotide) is a central molecule in cellular energy production and DNA repair. Every step of ATP synthesis inside mitochondria, and every action of the sirtuin family of longevity-related enzymes, consumes NAD+. NAD+ levels decline naturally with age. By age 50, levels can drop by up to 50% relative to young adulthood, and that drop is the entry point for the longevity-industry thesis: replace the lost NAD+ and the downstream effects of aging will slow.

Miraculous In Mice, Not Yet In Humans

The framing problem is that most of the dramatic preclinical evidence comes from rodents. Dr. Samuel Klein, quoted in the NPR piece, is blunt: “In rodents and mice, not in humans, NAD+ is miraculous.”

Most human studies have tested precursor compounds, NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide), rather than NAD+ itself. Small trials have produced promising signals in narrow populations: prediabetic women, newly-diagnosed Parkinson’s patients, and people with peripheral artery disease. None of these are general consumers of longevity products.

Dr. Christopher Martens, also quoted by NPR, framed the recurring pattern: “It’s not uncommon for things to work really well in mice and then not translate to humans.”

Where IV Infusions Sit On The Evidence Curve

The pricing structure inverts the evidence base. Pills, the cheapest tier, have the most data and a generally clean safety profile in short-term trials. Injectables, which cost more, have less published data. IV infusions, the priciest option, have the thinnest published human trial record.

Short-term safety signals from IV infusion studies aren’t trivial either. Reports include moderate-to-severe abdominal cramping, diarrhea, nausea, and vomiting. Long-term risks are unknown. There is no standardized dosing protocol agreed across clinics offering the infusions.

Two Separate Safety Conversations

It’s worth separating two product categories that get blended in headlines. Oral NR and NMN precursor supplements have shown a reasonably mild safety profile in published short-term trials. The IV infusion business is a different conversation, with the gastrointestinal side-effect cluster above and no comparable durability data.

The FDA has not approved any NAD+ or precursor product as a drug. Every product currently sold is in the dietary supplement category, which means efficacy claims carry far weaker verification requirements than pharmaceuticals would face.

The Question Marketing Skips For Women

A large share of NMN consumer marketing is targeted at women navigating perimenopause, ovarian function decline, bone density, and visible skin aging. Yet randomized, placebo-controlled trials in menopausal women that hit their primary endpoint with NMN are still few. The small insulin sensitivity studies in prediabetic women get cited as evidence for the whole demographic, which is a leap.

Women on hormone therapy, those undergoing cancer treatment, those with autoimmune conditions, and those already taking comprehensive multivitamins should think of NMN as a conversation with a clinician, not a casual addition to the cart.

What Has The Most Evidence

The legitimate scientific interest in NAD+ biology hasn’t disappeared, and dismissing the entire category would be unfair. The honest summary is that current marketing outpaces current human evidence for the average consumer.

What does work and has data: high-intensity interval training and resistance exercise both directly stimulate mitochondrial NAD+ recycling. Time-restricted eating windows of 14 to 16 hours activate NAD+-dependent sirtuins. Tryptophan-rich foods like eggs, dairy, turkey, and nuts supply the building blocks. Vitamin B3 (niacin) at the standard dietary intake (14 mg for women, 16 mg for men) provides direct NAD+ precursor.

Spending $100 a month on supplements before optimizing protein intake, sleep quality, and three resistance training sessions per week likely produces a smaller NAD+ recovery than the inverse order would. And that data is settled.

Source

NPR, “Marketers say NAD+ pills and infusions can boost longevity. What’s the evidence?” (May 11, 2026) — https://www.npr.org/2026/05/11/nx-s1-5813664/nad-infusions-supplements-longevity-science

Rolling Stone, “The Best NMN Supplements for 2026, According to Experts”